80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]施宏瑩,謝嘉儀,陳小青,等.類風濕關節(jié)炎并發(fā)肌少癥的危險因素分析[J].福建醫(yī)藥雜志,2023,45(02):1-4.
　SHI Hongying,XIE Jiayi,CHEN Xiaoqing,et al.Risk factor analysis of sarcopenia in rheumatoid arthritis[J].FUJIAN MEDICAL JOURNAL,2023,45(02):1-4.
點擊復制

類風濕關節(jié)炎并發(fā)肌少癥的危險因素分析()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期數(shù):
2023年02期
頁碼:
1-4
欄目:
臨床研究
出版日期:
2023-04-15

文章信息/Info

Title:
Risk factor analysis of sarcopenia in rheumatoid arthritis
文章編號:
1002-2600(2023)02-0001-04
作者:
施宏瑩; 謝嘉儀1; 陳小青2; 顏麗笙; 周明宣
福建醫(yī)科大學附屬第二醫(yī)院（泉州 362000）
Author(s):
SHI Hongying;  XIE Jiayi;  CHEN Xiaoqing;  YAN Lisheng;  ZHOU Mingxuan
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China
關鍵詞:
類風濕關節(jié)炎; 肌少癥; 肌抑素
Keywords:
rheumatoid arthritis; sarcopenia; myostatin
分類號:
R593.22
文獻標志碼:
B
摘要:
目的 分析類風濕關節(jié)炎（rheumatoid arthritis，RA）并發(fā)肌少癥的危險因素。方法 收集我院門診RA患者123例的臨床資料、骨密度、體成分、血清肌生成抑制素，將臨床資料完整的100例患者分為肌少癥組（20例）和無肌少癥組（80例）。比較兩組的臨床特征及肌抑素水平，采用二元邏輯回歸分析可能與RA并發(fā)肌少癥相關的因素。結(jié)果 RA患者中肌少癥發(fā)生率17.89%。與無肌少癥組相比，肌少癥組RA病程較長（P=0.028），關節(jié)腫痛數(shù)、ESR、CRP、IL-6、DAS28及HAQ評分、低骨量/骨質(zhì)疏松發(fā)生率、激素使用率顯著增高（P=0.000～0.009）。兩組脂肪含量指數(shù)（FMI）比較，差異無統(tǒng)計學意義（P>0.05）。兩組血清肌抑素水平比較，差異無統(tǒng)計學意義（P>0.05）。結(jié)論 RA病程長且疾病控制不佳易并發(fā)肌少癥，IL-6是RA相關肌少癥的獨立危險因素。
Abstract:
Objective To analyze the risk factors of sarcopenia in patients with rheumatoid arthritis (RA). Methods The clinical data, bone mineral density, body composition and serum myostatin of RA patients in the Second Affiliated Hospital of Fujian Medical University from June 2019 to December 2020 were collected and divided into sarcopenia group and non-sarcopenia group. The clinical characteristics and myostatin levels of the two groups were compared. Binary logistic regression analysis was used to analyze the factors that might be associated with RA complicated with sarcopenia. Results The prevalence of sarcopenia in RA was 17.89%.Compared with the RA with non-sarcopenia group, the duration of RA was longer (P=0.028), swollen joint count, tender joint count, ESR, CRP, IL-6, DAS28 and HAQ scores, the incidence rate of osteoporosis/osteopenia, and the hormone usage rate were significantly higher in the RA with sarcopenia group (P=0.000-0.009). There was no significant difference in fat mass index（FMI) between the two groups (P=0.092). There was no significant difference in serum myostatin level between the two groups (P>0.05). Conclusion The long course of RA and poor disease control may lead to sarcopenia. IL-6 is an independent risk factor for RA-associated sarcopenia.

參考文獻/References:

[1] Lin J Z,Liang J J,Ma J D,et al.Myopenia is associated with joint damage in rheumatoid arthritis: a cross-sectional study[J].J Cachexia Sarcopenia Muscle,2019,10(2): 355-367.
[2] Brance M L,Di Gregorio S,Pons-Estel B A,et al.Prevalence of sarcopenia and whole-body composition in rheumatoid arthritis[J].J Clin Rheumatol,2021,27(6): 153-160.
[3] Arnett F C,Edworthy S M,Bloch D A,et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J].Arthritis Rheum,1988,31(3): 315-324.
[4] Aletaha D,Neogi T,Silman A J,et al.2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative[J].Arthritis Rheum,2010,62(9): 2569-2581.
[5] Fransen J,van Riel P L.The disease activity score and the EULAR response criteria[J].Rheum Dis Clin North Am,2009,35(4): 745-757.
[6] Ward R J,Roberts C C,Bencardino J T,et al.ACR Appropriateness criteria osteoporosis and bone mineral density[J].J Am Coll Radiol,2017,14(5): 189-202.
[7] Chen L K,Woo J,Assantachai P,et al.Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J].J Am Med Dir Assoc,2020,21(3): 300-307.
[8] Cruz-Jentoft A J,Bahat G,Bauer J,et al.Sarcopenia: revised European consensus on definition and diagnosis[J].Age Ageing,2019,48(1): 16-31.
[9] Petermann-Rocha F,Chen M,Gray S R,et al.Factors associated with sarcopenia: a cross-sectional analysis using UK Biobanks[J].Maturitas,2020(133): 60-67.
[10] Müller R,Kull M,Plluste K,et al.Factors associated with low lean mass in early rheumatoid arthritis: a cross-sectional study[J].Medicina (Kaunas),2019,55(11)：730.
[11] Bian A L,Hu H Y,Rong Y D,et al.A study on relationship between elderly sarcopenia and inflammatory factors IL-6 and TNF-α[J].Eur J Med Res,2017,22(1): 25.
[12] Tournadre A,Pereira B,Dutheil F,et al.Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis[J].J Cachexia Sarcopenia Muscle,2017,8(4): 639-646.
[13] Yamada Y,Tada M,Mandai K,et al.Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study[J].Clin Rheumatol,2020,39(6): 1757-1764.
[14] Binkley N,Buehring B.Beyond FRAX: its time to consider "sarco-osteopenia"[BF][[BFQ]J].J Clin Densitom,2009,12(4): 413-416.
[15] Mendias C L,Bakhurin K I,Gumucio J P,et al.Haploinsufficiency of myostatin protects against aging-related declines in muscle function and enhances the longevity of mice[J].Aging Cell,2015,14(4): 704-706.
[16] Ju C R,Chen R C.Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease[J].Respir Med,2012,106(1): 102-108.
[17] Becker C,Lord S R,Studenski S A,et al.Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept,randomised,phase 2 trial[J].Lancet Diabetes Endocrinol,2015,3(12): 948-957.

相似文獻/References:

[1]許桂平,林帆.肌少癥的臨床研究進展[J].福建醫(yī)藥雜志,2017,39(4):5.

備注/Memo

備注/Memo:
基金項目：福建省自然科學基金資助項目（2021J01279）；泉州市科技計劃項目(2019C071R)
1 贛南醫(yī)學院第一附屬醫(yī)院；2 通信作者，Email：[email protected]
更新日期/Last Update: 2023-04-15